Journal of Medical Biochemistry · 2011 · 19 citations · 9 references
MedicineCardiologyInternal MedicineClinical CardiologyClinical EpidemiologyLipid BiochemistryAcute Coronary SyndromesCardiac BiomarkersCardiac Risk AssessmentCardiovascular DiseaseIschemic Heart DiseaseLipoprotein AnalysisAcute Coronary Syndrome BiomarkersAcute Coronary Syndrome Risk StratificationApolipoprotein QuantificationAtherogenic Lipoprotein AssessmentCardiovascular Risk DetectionCardiovascular Risk Stratification Using LipoproteinsLipid Risk AssessmentLipoprotein Phenotyping
How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes Acute coronary syndromes are the leading cause of hospitalization and death. Results from recent studies suggest that apolipoprotein measurement and apoB:apoA-I are superior to traditional lipids in the estimation of coronary risk. We compared apolipoprotein concentrations and apoB:apoA-I with traditional lipid measures and atherogenic indices in patients diagnosed with acute coronary syndromes (ACS) within 6 hrs from the onset of chest pain. A study group consisted of 227 patients diagnosed with ACS (STEMI=60, NSTEMI=66 and UA=105). Clinically healthy volunteers (n=85) served as controls. Measurements of cardiac TnI, lipid profile, hsCRP, apolipoprotein A-I and apoB100 were performed and apoB:apoA-I, TC-HDL-C, LDL-C:HDL-C ratios were calculated. Patients had increased LDL-C (>3.0 mmol/L) and non-HDL-C (>3.4 mmol/L). Triglycerides were below the cut-off value, but patients had significantly higher TG concentrations and lower HDL-C compared to controls (p<0.001). Apo B and apoA-I concentration in patients remained within the accepted range. Atherogenic indices TC:HDL-C, LDL-C:HDL-C and apoB:apoA-I were significantly increased in patients. ApoB:apoA-I ratio in ACS males was within low risk whereas in females corresponded to medium risk. ApoB:apoA-I and LDL-C:HDL-C ratios were of good diagnostic utility for discrimination between patients and controls (AUC 0.71 and 0.79; respectively). ApoB:apoA-I and LDL-C:HDL-C were of very good diagnostic utility for discrimination between STEMI patients and controls (AUC 0.80 and 0.84). We could not show the superiority of apoB:apoA-I over LDL-C:HDL-C as the discrimination power of both was almost identical. Determination of apolipoproteins should not be recommended for routine clinical use, however, incorporating apoB and apoB:apoA-I into risk assessment could provide additional important information on cardiovascular risk.
9
Philip J. Barter, Christie M. Ballantyne, Rafael Carmena et al. · Journal of Internal Medicine · 2006 · 471 citations · Full text
Santica M. Marcovina, J J Albers, L. Omar Henderson et al. · Clinical Chemistry · 1993 · 344 citations
Increased Small Low-Density Lipoprotein Particle Number
Sekar Kathiresan, James D. Otvos, Lisa Sullivan et al. · Circulation · 2005 · 322 citations
S Marcovina, J J Albers, Hal Kennedy et al. · Clinical Chemistry · 1994 · 243 citations